August 20, Blueprint Medicines is working with The Life Raft Group and GIST Support International to host a webinar providing a data update from the registration-enabling NAVIGATOR trial of the investigational treatment avapritinib in patients with PDGFRA Exon 18 mutant GIST and fourth-line GIST.